Stock DNA
Pharmaceuticals & Biotechnology
GBP 212,353 Million ()
28.00
NA
231.02%
0.61
21.68%
6.23
Revenue and Profits:
Net Sales:
10,823 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,833 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.55%
0%
20.55%
6 Months
36.51%
0%
36.51%
1 Year
41.21%
0%
41.21%
2 Years
79.35%
0%
79.35%
3 Years
98.15%
0%
98.15%
4 Years
144.38%
0%
144.38%
5 Years
108.84%
0%
108.84%
AstraZeneca PLC for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
16.15%
EBIT Growth (5y)
25.50%
EBIT to Interest (avg)
4.36
Debt to EBITDA (avg)
1.85
Net Debt to Equity (avg)
0.61
Sales to Capital Employed (avg)
0.64
Tax Ratio
16.21%
Dividend Payout Ratio
69.15%
Pledged Shares
0
Institutional Holding
0.05%
ROCE (avg)
12.02%
ROE (avg)
15.16%
Valuation key factors
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
5.91
EV to EBIT
22.87
EV to EBITDA
14.54
EV to Capital Employed
4.17
EV to Sales
4.82
PEG Ratio
0.97
Dividend Yield
254.41%
ROCE (Latest)
18.25%
ROE (Latest)
21.42%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 10 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
10,823.40
10,254.10
5.55%
Operating Profit (PBDIT) excl Other Income
3,596.60
3,264.60
10.17%
Interest
328.70
351.10
-6.38%
Exceptional Items
15.70
-122.10
112.86%
Consolidate Net Profit
1,832.70
1,528.10
19.93%
Operating Profit Margin (Excl OI)
236.20%
219.50%
1.67%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 5.55% vs 12.44% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 19.93% vs 5.11% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
42,316.90
36,853.70
14.82%
Operating Profit (PBDIT) excl Other Income
13,972.30
11,540.10
21.08%
Interest
1,088.60
910.70
19.53%
Exceptional Items
-2,460.50
-1,635.50
-50.44%
Consolidate Net Profit
5,510.20
4,795.50
14.90%
Operating Profit Margin (Excl OI)
236.50%
205.40%
3.11%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 14.82% vs 2.36% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 14.90% vs 79.38% in Dec 2023
About AstraZeneca PLC 
AstraZeneca PLC
Pharmaceuticals & Biotechnology
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.
Company Coordinates 
Company Details
1 Francis Crick Avenue , CAMBRIDGE None : CB2 0AA
Registrar Details






